UK markets close in 8 hours 2 minutes
  • FTSE 100

    7,919.00
    +33.83 (+0.43%)
     
  • FTSE 250

    20,375.55
    +71.74 (+0.35%)
     
  • AIM

    885.03
    +1.80 (+0.20%)
     
  • GBP/EUR

    1.1282
    +0.0018 (+0.16%)
     
  • GBP/USD

    1.2128
    +0.0058 (+0.48%)
     
  • BTC-GBP

    18,744.05
    -487.03 (-2.53%)
     
  • CMC Crypto 200

    523.60
    -13.29 (-2.48%)
     
  • S&P 500

    4,117.86
    -46.14 (-1.11%)
     
  • DOW

    33,949.01
    -207.68 (-0.61%)
     
  • CRUDE OIL

    78.66
    +0.19 (+0.24%)
     
  • GOLD FUTURES

    1,893.70
    +3.00 (+0.16%)
     
  • NIKKEI 225

    27,584.35
    -22.11 (-0.08%)
     
  • HANG SENG

    21,624.36
    +340.84 (+1.60%)
     
  • DAX

    15,602.96
    +190.91 (+1.24%)
     
  • CAC 40

    7,198.71
    +78.88 (+1.11%)
     

Sartorius confirms 2022 revenues target

BERLIN (Reuters) - Franco-German lab supplies maker Sartorius said on Thursday that 2022 full-year sales were on target but predicted growth in 2023 would not be as strong amid demand normalization and further declines in the COVID-19-related business.

Sales growth rose by 15% in constant currencies, according to preliminary figures, Sartorius said. In October, Sartorius predicted consolidated 2022 sales revenue growth would be in the lower half of the range of around 15% to 19%.

"While growth in the Lab division was even slightly stronger than forecast, the Bioprocess division was influenced by the expected normalization of demand, a process that is expected to continue for several quarters," said Chief Executive Joachim Kreuzberg.

The Bioprocess Solutions division, which supplies substances and gear to biopharmaceutical companies, saw a 15.9% increase. However, incoming orders dropped over 10% in the division that was particularly affected by the pandemic.

For 2023, the company expects sales revenue growth in the low single-digit percentage range; excluding the COVID-19-related business, the increase would be in the high single-digit range.

Citing inflation adjustments, the company slightly raised its medium-term sales revenue target on Thursday and now expects to hit around 5.5 billion euros ($6.01 billion) in 2025, from a previous 5 billion euros.

($1 = 0.9156 euros)

(Writing by Miranda Murray; Editing by Paul Carrel)